Key points are not available for this paper at this time.
Should an artificial intelligence (AI) program that appears to have a better success rate than human pathologists be used to replace or augment humans in detecting cancer cells? We argue that some concerns-the "black-box" problem (ie, the unknowability of how output is derived from input) and automation bias (overreliance on clinical decision support systems)-are not significant from a patient's perspective but that expertise in AI is required to properly evaluate test results.
Anderson et al. (Fri,) studied this question.